This website uses cookies to give you the best user experience. If you continue
without changing your settings we'll assume you are happy to receive all RSC cookies.
You can change your cookie settings by navigating to our Privacy and Cookies page and following the instructions. These instructions
are also obtainable from the privacy link at the bottom of any RSC page.
School of Chemistry, University of Leeds, Woodhouse Lane, Leeds, UK
E-mail: P.C.McGowan@leeds.ac.uk
; Fax: +44 (0)113436565
; Tel: +44 (0)1133436404
b
The Institute of Cancer Therapeutics, University of Bradford, West Yorkshire, UK
E-mail: R.M.Phillips@bradford.ac.uk
; Fax: +44 (0)1274233234
; Tel: +44 (0)1274235367
Dalton Trans., 2012,41, 13800-13802
DOI:
10.1039/C2DT32104A
Received
13 Aug 2012,
Accepted
13 Sep 2012
First published online
14 Sep 2012
Several Ru-arene and Ir–Cp* complexes have been prepared incorporating (N,N), (N,O) and (O,O) coordinating bidentate ligands and have been found to be active against both HT-29 and MCF-7 cell lines. By incorporating a biologically active ligand into a metal complex the anti-cancer activity is increased.
Fetching data from CrossRef. This may take some time to load.